Mirada Medical

Mirada Medical is a global company specializing in advanced medical imaging software designed to improve the speed and accuracy of cancer care. The firm originated from Professor Sir Mike Brady's Medical Vision Laboratory at the University of Oxford in the late 1990s and was officially formed in 2001 through the merger of two spin-out companies. After a series of acquisitions and a management buy-out led by Hugh Bettesworth in 2008, the company re-established its focus on responding to clinical needs with agility. In 2021, Jon DeVries, a tech veteran with experience at IBM Watson Health, was appointed CEO. Mirada Medical operates on a business-to-business (B2B) model, licensing its software to hospitals, cancer centers, and diagnostic imaging clinics worldwide, generating revenue through software subscriptions and licensing fees, including setup, support, and updates. They also partner with major healthcare and technology companies like GE Healthcare, Canon, and Varian to integrate their technology into existing systems, extending their global reach to over 2,000 hospitals. Mirada’s product portfolio leverages AI and deep learning to automate complex tasks in oncology workflows. Key products include Mirada XD, a vendor-neutral platform for diagnostic reading of multi-modal scans (e.g., PET/CT, PET/MR), and RTx, visualization software for radiotherapy planning. A notable innovation is DLCExpert™, an FDA-cleared AI solution that automates the contouring of organs and tumors on scans, which is crucial for radiation therapy planning and can reduce the required time by up to 75%. Additionally, Simplicit90Y™ offers personalized dosimetry planning for targeted liver cancer treatments.